Open Heart

APRIL 24, 2024

Introduction Heart failure (HF) incidence is increasing in older adults with high hospitalisation and mortality rates. Frailty, chronic kidney disease and ischaemic heart disease increased significantly versus the first period (p<0.001). Treatment is complicated by side effects and comorbidities.

Heart Failure 52

Heart Failure Preserved Ejection Fraction ACE Inhibitor Pharmacology 52

The British Journal of Cardiology

JULY 17, 2024

2–4 The studies will be well-known to nephrologists and demonstrated that angiotensin-receptor blockers (ARBs) had anti-proteinuric effects and/or slowed the decline of kidney function in patients with diabetic kidney disease. Clinicians and health care systems must be encouraged to make use of these treatments.”

Kidney Disease 52

Kidney Disease Outcomes Diabetes Heart Failure 52

DAIC

APRIL 6, 2024

However, researchers said the drug may be helpful in reducing heart failure risks, including hospitalization, following a heart attack. All secondary endpoints related specifically to heart failure outcomes were significantly reduced among patients who received empagliflozin.

Heart attacks 98

Heart attacks Heart Attack Heart Failure Outpatient 98

DAIC

APRIL 6, 2024

While composite of death and heart failure hospitalizations was not significantly reduced, empagliflozin may help reduce heart failure risks after a heart attack, according to results from the EMPACT-MI trial presented on day one of the American College of Cardiology Scientific Sessions, ACC.24,

Heart attacks 81

Heart attacks Heart Attack Heart Failure Outcomes 81